Arlington, VA – May 8, 2018 – The Digital Therapeutics Alliance welcomes ten global thought leaders as 2018 Strategic Advisors. These individuals will engage with DTA leaders and members to establish and progress the Alliance’s goals and initiatives.
DTA launched in October 2017 through a collaboration of four digital therapeutics companies: Akili Interactive, Propeller Health, Voluntis, and WellDoc. Today, DTA also welcomes nine companies to membership: Bayer, Big Health, Cognoa, Kaia Health, Merck, Omada Health, Otsuka America Pharmaceutical, Inc., Pear Therapeutics, and Sanofi.
“DTA is committed to convening industry leaders that share a passion for crafting a strong future for the integration of tested, trustworthy digital solutions in healthcare,” said Pierre Leurent, CEO of Voluntis and DTA Board of Directors Chair.
In its first year, DTA will engage with patients, providers, payers, and regulators to define and develop meaningful resources to guide and scale this quickly evolving industry. The Alliance recognizes that this group of Strategic Advisors, from aligned industries beyond its membership, brings unique value and perspective to our core initiatives and projects.
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association with the mission of broadening the understanding, adoption, and integration of clinically-validated digital therapeutics into healthcare through education, advocacy, and research. To learn more please visit: www.dtxalliance.org.
The authors found that participants experienced several positive clinical outcomes, including a 78% reduction in rescue inhaler use and a 48% improvement in symptom-free days. The hundreds of thousands of crowdsourced real-world data points on inhaler use, combined with environmental data, also informed municipal policy recommendations, including enhancing tree canopy, tree removal mitigation, zoning for air pollution emission buffers, recommended truck routes, and development of a community asthma notification system.
New York Times (Natasha Singer) — Health tech companies are making a big push to digitize medicine, introducing novel tools like digital pills that track when patients take their drugs and smart spoons that can automatically adjust to hand tremors. Now they want some patients to get prescription treatments from the app store as well.
Later this year, doctors treating patients addicted to substances like cocaine and amphetamines will be able to prescribe Reset, an app that gives patients lessons to help them modify their behavior. The Food and Drug Administration cleared it in September as the first mobile medical app to help treat substance-use disorders.
STAT News (Casey Ross) — The pitches always sounded promising: A new software app could track glucose levels for people with diabetes or soothe the brains of insomniacs. Most pharma executives would politely smile and nod, but then park their money somewhere else. Not anymore.
MobiHealthNews (Dave Muoio) — From syringes to workflow management systems, healthcare is no stranger to adopting new technologies into standard care. As digital and connected technologies continue to stake their claim in the industry, the last few years have seen the rise of a new type of health technology product — one that promises measurable health outcomes validated by traditional clinical trials.
McKinsey & Company — Digital therapeutics have made much progress over the past decade, harnessing technology to supplement or potentially replace traditional clinical therapy. Some devices complement traditional treatment by helping patients manage their condition, including informing when and how much medication to take. And some offer alternative treatments to drugs, such as sensory stimuli delivered through a tablet computer to manage insomnia or depression.
The Economist — Luann Stottlemyer has had diabetes for 23 years, but it was only in 2016 that her doctor prescribed a treatment that changed her life. It has allowed her to bring her blood-sugar levels under control and lose weight. Yet this miracle of modern science is not a new pill. It is a smartphone app called BlueStar.
The Economist — This week three of the biggest names in American business—Amazon, Berkshire Hathaway and JPMorgan Chase—announced a new venture to provide better, cheaper health care for their employees. A fundamental problem with today’s system is that patients lack knowledge and control. Access to data can bestow both.
PharmaVoice (Denise Myshko) — Imagine instead of a pill, a doctor prescribes a game for a child with attention deficit disorder. Or imagine patients dealing with substance abuse being prescribed assessments they can do via a mobile device to track progress.
These software programs are part of a new class of therapeutics — digital medicines — that can lead to changes in behavior and provide clinical benefit. But digital therapeutics go beyond games or behavior modification programs; they are digital tools that have been tested in clinical trials to assess safety and efficacy. Digital therapeutics represent a new generation of healthcare that use innovative, clinically validated disease management, and treatment technologies to enhance, and in some cases replace, current medical practices and treatments.
Magellan Health, Inc. has long been the national leader in the use of digital innovation to help those struggling with various medical and behavioral conditions, including Substance Use Disorders (SUD). As a pioneer in the use of digital therapeutics and computerized cognitive behavioral therapy (CCBT), Magellan has engaged in a new initiative designed to measure clinical outcomes in patients with SUD by leveraging reSET®, the first ever FDA cleared prescription digital therapeutic from PEAR Therapeutics.